eletriptan hydrobromide

FDA Drug Profile — eletriptan hydrobromide, Eletriptan Hydrobromide, Relpax

eletriptan hydrobromide is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand names including eletriptan hydrobromide, Eletriptan Hydrobromide, Relpax. Available dosage forms: tablet, film coated, tablet.

Drug Details

Generic Name
eletriptan hydrobromide
Brand Names
eletriptan hydrobromide, Eletriptan Hydrobromide, Relpax
Application Number
ANDA205186
Sponsor
Quality Care Products, LLC
NDC Codes
7
Dosage Forms
TABLET, FILM COATED, TABLET
Routes
ORAL
Active Ingredients
ELETRIPTAN HYDROBROMIDE

Indications and Usage

1 INDICATIONS AND USAGE Eletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks. • Eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks. • Safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache. Eletriptan hydrobromide tablets are a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use: • Use only after a clear diagnosis of migraine has been established ( 1 ) • Not indicated for the prophylactic therapy of migraine ( 1 ) • Not indicated for the treatment of cluster headache ( 1 )